Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
暂无分享,去创建一个
K. Harrington | H. Kaufman | M. Middleton | F. Collichio | R. Andtbacka | G. Downey | Katarina Ӧhrling